Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Mol Pharm. 2010 Aug 2;7(4):936–943. doi: 10.1021/mp100054m

Figure 2.

Figure 2

Longitudinal relaxivity rate (left) and transverse relaxivity rate (right) of peptide CLT1-targeted G3-DOTA-Mn (P-G3-Mn) and the control nanoglobular conjugate G3-DOTA-Mn (G3-Mn) as a function of Mn(II) concentration.